Oncologist David Scadden explores the hypothesis that cancer grows from stem cells and how future cancer treatment might focus on stem cells, not the whole tumor.
Harvard Professor David Scadden envisions a future where medicines activate stem cells already in our bodies. The pharmaceutical industry is taking notice.
David T. Scadden is Professor of Medicine at Harvard Medical School and Director of the Massachusetts General Hospital Center for Regenerative Medicine and Technology. He also is Co-Director of the Harvard Stem Cell Institute. Dr. Scadden’s research focuses on reconstituting immune function using the stem cells that form blood cells to fight cancer and AIDS. He an expert in the treatment of HIV-related Kaposi's sarcoma and B-cell lymphoma and has developed a number of new therapies for them.
Dr. Scadden received his training at the Brigham and Women’s Hospital and Dana-Farber Cancer Institute.
He has received numerous honors and awards, including the Alpha Omega Alpha; Edwin C. Garvin, MD Senior Prize; Doris Duke Innovation in Clinical Research Award; the Burroughs Welcome Fund Clinical Scientist Award in Translational Research; and the Brain Tumor Society's Alan Goldfine Leadership Chair of Research.